Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries
FOSTER CITY, Calif., December 1, 2016 — Gilead Sciences announced that its HIV medicines now reach an estimated 10 million people living in low- and middle-income countries. This represents nearly two-thirds of people currently on HIV treatment in the developing world.
"Over the past decade, the number of people accessing HIV therapy in the developing world has increased greatly, and I want to thank our partners around the world who have helped make this possible," said Gregg Alton, Executive Vice President, Commercial and Access Operations ALA, Corporate and Medical Affairs, Gilead Sciences. "Despite this substantial progress, more than 20 million people are still in need of treatment. Closing this treatment gap will take a continued collective effort and we are committed to working with the global health community, and our partners, to address remaining access barriers."
Gilead has been at the forefront of advancing the care of people living with HIV for more than 25 years, helping transform HIV infection from an often fatal and debilitating disease into a chronic, manageable condition for many. While the discovery of new drugs has helped millions of people, ensuring that people around the world have access to the latest treatments is just as important, and the company operates a dedicated business unit focused on expanding access to its medicines for people living in developing countries.
Gilead enables access to its medicines in developing countries through various strategies that have evolved over the years. These strategies include:
- Transparent and timely regulatory submissions of drug dossiers;
- No-profit and steeply discounted prices on our branded medicines — the company recently extended its no-profit HIV drug prices to 22 middle-income countries for the first time;
- Licensing agreements with generic manufacturers that have led to an 80 percent reduction in the cost of Gilead HIV medicines over the last ten years;
- Demonstration projects and pilot programs;
- Training for nurses, doctors and community health workers;
- Supply chain management;
- Grants for prevention and care programs;
- Strategic partnerships and donation programs designed to reach vulnerable populations.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.